Rituximab Ç×¾ÏÈÇпä¹ý¿¡ ´ëÇÑ ¾à»çÀÇ È¯ÀÚ ±³À° °³¼± ¹× Àû¿ë È¿°ú
Effects of the Improved Method in Patient Education on Rituximab Chemotherapy by Pharmacists
º´¿ø¾à»çȸÁö 2014³â 31±Ç 2È£ p.724 ~ p.734
ÇÑ¿µÇö(Han Young-Hyun) - °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¾àÁ¦ºÎ
¹Ú¾Ö·É(Park Ae-Ryoung) - °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¾àÁ¦ºÎ
±è¼øÁÖ(Kim Soon-Joo) - °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¾àÁ¦ºÎ
À̺´±¸(Lee Byung-Koo) - ÀÌÈ¿©ÀÚ´ëÇб³ ¾àÇдëÇÐ
³ªÇö¿À(La Hyen-O) - °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¾àÁ¦ºÎ
Abstract
Rituximab is a monoclonal antibody approved for the treatment of non-Hodgkin¡¯s lymphoma. Infusion-related reactions have been reported in 50% of the patients within 1-2 hours of starting the infusion. The patient education had been performed after the administration of rituximab, due to heavy work-load during the morning shift at Seoul St. Mary¡¯s Hospital. Therefore, an improvement in education method for rituximab-containing chemotherapy was required. The purpose of this study was to evaluate the improved education method and the result of the application of new method.
The patients in this study were over 19 years of age, who received the first combination chemotherapy including rituximab, at Seoul St. Mary¡¯s Hospital from May 2011 to January 2012. The patients who received the education previous to improvement were the control group (n=20), and patients who received the improved education were the study group (n=20). The improved education was performed on the patients before and during the rituximab administration, respectively. The contents of the education were the same before and after the improvement. In the control group, 13 patients experienced subjective side effects, and 6 of those patients immediately reported their conditions (6/13, 46.2%). In the study group, 9 patients out of 11 immediately reported their subjective side effects (9/11, 81.8%), and this result was not statistically significant (p=0.270). The points of the recognition for hypersensitivity were shown to be 50.0¡¾25.6 and 67.2¡¾22.6 in the control and study groups, respectively, and this was significantly higher in the study group (p=0.031). The patient¡¯s understanding, needs, and satisfaction from the education were shown to be 68.9¡¾14.0 and 65.0¡¾20.6 (p=0.612), 74.3¡¾14.0 and 75.0¡¾19.4 (p=0.904), and 80.6¡¾14.4 and 81.3¡¾13.1 (p=0.943), in the control and study groups, respectively.
The new education methods focusing on hypersensitivity to rituximab improved on the recognition and the management of hypersensitivity reactions.
Å°¿öµå
Rituximab, Patient education, Infusion reaction
KMID :
0869620140310020724
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)